Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis

Journal of Clinical Pharmacology

Volumn 37, Issue 7, 1997, Pages 610-617

  Vadiei, Kiumars ^a   Troy, Steven ^a   Korth Bradley, Joan ^a   Chiang, Soong T ^a   Zimmerman, James J ^a  

^a WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE KIDNEY FUNCTION RELATION; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; HEART EJECTION FRACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PLASMA CLEARANCE; SEX DIFFERENCE;

EID: 0030808985     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04343.x     Document Type: Article

References (32)

1. Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przybylksi J, Levi RJ, et al: Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol 1976; 38:934-944.
2. Heger JJ, Prystowsky EN, Jackman WM, Naccarelli GV, Warfel KA, Pinkenberger RL, Zipes DP: Clinical efficacy and electrophysiology during long-term therapy for recurrent tachycardia or ventricular fibrillation. N Engl J Med 1981; 305:539-545.
3. Green HL: The efficacy of amiodarone in the treatment of ventricular tachycardia or ventricular fibrillation. Prog Cardiovasc Dis 1989; 31:319-354.
4. Koean HA, Horowitz LN: Efficacy and toxicity of amiodarone for the treatment of supraventricular tachyarrhythmias. Prog Cardiovasc Dis 1980; 31:355-366.
5. Vaughn Williams EM: Classification of anti-arrhythmic drugs. In, Sandoe E, Flensted-Jansen E, Olesen KH (eds.): Symposium on Cardiac Arrhythmias. Sodertalje, Sweden: AB Astra, 1970; 449-472.
6. Vaughn Williams EM: Classifying antiarrhythmic actions: by facts or speculation. J Clin Pharmacol 1992; 32:964-977.
7. Singh BN, Venkatesh N, Nademanee K, Josephson MA, Kannan R: The historical development, cellular electrophysiology and pharmacology of amiodarone. Prog Cardiovasc Dis 1989; 31:249-280.
8. Frumin H, Behrens S, Martyn R, Goldberg MJ, Rubenfire M, Kerin N: Hemodynamic effects of antiarrhythmic drugs. J Clin Pharmacol 1991; 31:1070-1080.
9. Singh BN: Amiodarone: pharmacological, electrophysiological, and clinical profile of an unusual antiarrhythmic compound. In, Singh BN, Wellens HJJ, Hiraoka M (eds.): Electropharmacological Control of Cardiac Arrhythmias. Mount Kisko, NY: Futura, 1994; 497-522.
10. Bopp P, Rasoamanambelo L, Crevoisier JL, Barthelemy JC, Lomazzi F, Campanini C, Frangos A: Acute hemodynamic effects of intravenous amiodarone in patients with coronary artery disease. J Cardiovasc Pharmacol 1985; 7:286-289.
11. Munoz A, Karila P, Gallay P, Zettelmeire F, Messner P, Mery M, et al: A randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80. Eur Heart J 1988; 9:142-148.
12. Schwartz A, Shen E, Morady F, Gilliespie K, Scheinman M, Chatterjee K: Hemodynamic effects of intravenous amiodarone in patients with depressed left ventricular function and recurrent ventricular tachycardia. Am Heart J 1983; 106:848-856.
13. Remme WJ, Van Hoogenhuyze DC, Krauss XH, Hofman A, Kruyssen DA, Storm CJ: Acute hemodynamic and antiischemic effects of intravenous amiodarone. Am J Cardiol 1985; 55:639-644.
14. Freedman MD, Somberg JC: Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol 1991; 31:1061-1069.
15. Ujhelyi MR, Klamerus KJ, Vadiei K, O'Rangers E, Izard M, Neefe L, et al: Disposition of intravenous amiodarone in subjects with normal and impaired renal function. J Clin Pharmacol 1996; 36:122-130.
16. Vadiei K, O'Rangers EA, Klamerus KJ, Kluger J, Kazierad DJ, Leese PT, et al: Pharmacokinetics of intravenous amiodarone in patients with impaired left ventricular function. J Clin Pharmacol (in press).
17. Zimmerman JJ, Giel SJ, Klamerus KJ: Effect of age on the pharmacokinetics of intravenously administered amiodarone. J Clin Pharmacol (in press).
18. Adams PC, Holt DW, Storey GC, Morley AR, Callaghan J, Campbell RW: Amiodarone and its desethyl-metabolite: tissue distribution and nonphysiological changes during long-term therapy. Circulation 1985; 72:1064-1075.
19. Anastasiou-Nana M, Levis GM, Moulopoulos S: Pharmacokinetics of amiodarone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol 1982; 20:524-529.
20. Veronese ME, McLean S, Hendriks R: Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel-glass-binding method. Br J Clin Pharmacol 1988; 26:721-731.
21. Neyroz P, Bonati M: In vitro amiodarone protein binding and its interaction with warfarin. Experientia 1985; 41:361-363.
22. Holt DW, Tucker ET, Jackson PR, Storey GCA: Amiodarone pharmacokinetics. Am Haart J 1983; 106:840-847.
23. Harris L, Hind CR, McKenna WJ, Savage C, Krikler SJ, Storey GC, et al: Renal elimination of amiodarone and its desethyl metabolite. Postgrad Med J 1983; 59:440-442.
24. Somani P: Basic and clinical pharmacology of amiodarone: relationship of antiarrhythmic effects, dose, and drug concentrations in intracellular inclusion bodies. J Clin Pharmacol 1989; 29:405-412.
25. Beal SL, Boeckman J, Scheiner LB: NONMEM Users Guides. Version 3, Level 1.2. NONMEM Project Group, University of California, San Francisco, 1989.
26. Storey GCA, Holt DW: High-performance liquid chromatographic measurement of amiodarone and desethylamiodarone in plasma or serum at the concentrations attained following single 400-mg dose. J Chromatogr 1982; 245:377-380.
27. Gibaldi M, Perier D: Pharmacokinetics. Second Edition. New York: Marcel Dekker, 1982.
28. Sloskey GE: Amiodarone: a unique antiarrhythmic agent. Clin Pharm 1983; 2:330-340.
29. Roden DM: Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol 1993; 72:45F-50F.
30. Korth-Bradley J, Rose GM, de Vane P, Peters J, Chiang ST: Population pharmacokinetics of intravenous amiodarone in patients with refractory ventricular tachycardia/fibrillation. J Clin Pharmacol 1996; 36:715-719.
31. Gibaldi M: Pharmacokinetic variability-body weight, age, sex, and genetic factors. In, Biopharmaceutics and Clinical Pharmacokinetics. Fourth Edition. Philadelphia: Lea & Febiger, 1991; 234-271.
32. Wilkinson GR: Clearance approaches in pharmacology. Pharmacol Rev 1987; 39:1-47.